Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Chief Medical Officer | January 11, 2021 | January 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date January 11, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.20 · Expires 2031-01-10 | Direct | 450,000 |
Reported balance
After 2021-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-11 · Grant · Acquired 450,000 · Balance 450,000 F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allakos Inc.
Report date May 15, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.55 · Expires 2033-08-01 | Direct | 0 |
Reported balance
After 2025-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-15 · Disposition to issuer · Disposed 154,786 · Balance 0 F1: This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2034-05-24 | Direct | 0 |
Reported balance
After 2025-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-15 · Disposition to issuer · Disposed 41,000 · Balance 0 F1: This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F2: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F3: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F3: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Principia Biopharma Inc.
Report date September 28, 2020 · Filed September 28, 2020
Section 16 reporting ended · disclosed 2020-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 1
1 source rowRow 1 · 2020-09-28 · Other · Disposed 2,207 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. F2: Includes 381 shares acquired under the Employment Stock Purchase Plan on September 25, 2020. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.77 · Expires 2028-10-22 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-28 · Disposition to issuer · Disposed 168,057 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.31 · Expires 2030-03-04 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-09-28 · Disposition to issuer · Disposed 55,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: Includes 381 shares acquired under the Employment Stock Purchase Plan on September 25, 2020.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 15, 2025 16:06 UTC | Allakos Inc. ALLK · Entity 79644 | Disposition to issuerStock Option (right to buy) · Derivative | 41,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001104659-25-049419 · tm2514731-7_4seq1.xml · derivative · entry 2 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,000 shares Expires 2034-05-24 F1 · derivative.exercise_date: This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. Read SEC document |
| May 15, 2025 Filed May 15, 2025 16:06 UTC | Allakos Inc. ALLK · Entity 79644 | Disposition to issuerStock Option (right to buy) · Derivative | 154,786 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001104659-25-049419 · tm2514731-7_4seq1.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 154,786 shares Expires 2033-08-01 F1 · derivative.exercise_date: This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. Read SEC document |
| May 24, 2024 Filed May 29, 2024 16:05 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 41,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0000950170-24-065906 · ownership.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2034-05-24 F1 · derivative.exercise_date: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,300 | $26.12 Strike: $13.88 | $347,396.00 |
DisclosureSEC source: 0001209191-23-045430 · doc4.xml · derivative · entry 4 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F3 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,948 | $23.19 Strike: $16.81 | $137,934.12 |
DisclosureSEC source: 0001209191-23-045430 · doc4.xml · derivative · entry 3 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F3 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,522 | $25.23 Strike: $14.77 | $593,460.06 |
DisclosureSEC source: 0001209191-23-045430 · doc4.xml · derivative · entry 2 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F2 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 13,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045430 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 18:03 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 154,786 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001209191-23-044535 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,786 Underlying: Common Stock · 154,786 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option vests as to one thirty-sixth (1/36) of the shares monthly over a three year period, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:21 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033186 · doc4.xml · derivative · entry 2 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. F3 · derivative.expiration_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:21 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033186 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 16:35 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | PurchaseCommon Stock | 300 | $21.20 | $6,360.00 |
DisclosureSEC source: 0001209191-22-048759 · doc4.xml · nonDerivative · entry 2 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 16:35 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | PurchaseCommon Stock | 9,700 | $21.22 | $205,834.00 |
DisclosureSEC source: 0001209191-22-048759 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,700 Read SEC document |
| May 26, 2022 Filed May 31, 2022 18:25 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Unit · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032960 · doc4.xml · derivative · entry 2 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires 2023-05-26 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: 100% of the RSUs will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 18:25 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 13,300 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-22-032960 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F1 · derivative.exercise_date: 100% of the stock option will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:38 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 5,948 | $0.00 Strike: $16.81 | $0.00 |
DisclosureSEC source: 0001209191-21-038800 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 4, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:20 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-21-003422 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2031-01-10 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 23,522 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-20-054250 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,522 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on November 6, 2020 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:16 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 55,000 | Not disclosed Strike: $67.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-052226 · doc4.xml · derivative · entry 4 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2030-03-04 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:16 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $35.42 | Not disclosed |
DisclosureSEC source: 0001209191-20-052226 · doc4.xml · derivative · entry 3 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:16 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 168,057 | Not disclosed Strike: $23.77 | Not disclosed |
DisclosureSEC source: 0001209191-20-052226 · doc4.xml · derivative · entry 2 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,057 shares Expires 2028-10-22 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:16 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | OtherCommon Stock | 2,207 | $100.00 | $220,700.00 |
DisclosureSEC source: 0001209191-20-052226 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. F2 · shares: Includes 381 shares acquired under the Employment Stock Purchase Plan on September 25, 2020. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:17 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.77 | $0.00 |
DisclosureSEC source: 0001209191-20-047842 · doc4.xml · derivative · entry 3 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,057 Underlying: Common Stock · 15,000 shares Expires 2028-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 22, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:17 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 15,000 | $100.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-20-047842 · doc4.xml · nonDerivative · entry 2 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,826 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:17 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionCommon Stock | 15,000 | $23.77 | $356,550.00 |
DisclosureSEC source: 0001209191-20-047842 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:01 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.77 | $0.00 |
DisclosureSEC source: 0001209191-20-043008 · doc4.xml · derivative · entry 3 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,057 Underlying: Common Stock · 15,000 shares Expires 2028-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 22, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:01 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 15,000 | $80.07 | $1,201,069.50 |
DisclosureSEC source: 0001209191-20-043008 · doc4.xml · nonDerivative · entry 2 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,826 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $80.00 to $80.28 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:01 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionCommon Stock | 15,000 | $23.77 | $356,550.00 |
DisclosureSEC source: 0001209191-20-043008 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,332 shares shares acquired under the Employment Stock Purchase Plan on May 15, 2020. Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 17:28 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $67.31 | $0.00 |
DisclosureSEC source: 0001209191-20-016693 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-03-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 5, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 21:00 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 495 | $60.00 | $29,700.00 |
DisclosureSEC source: 0001209191-19-061667 · doc4.xml · nonDerivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494 F1 · balance_after: Includes 493 shares and 496 shares acquired under the Employment Stock Purchase Plan on May 15, 2019 and November 15, 2019 respectively. Read SEC document |
| March 01, 2019 Filed Mar 8, 2019 17:40 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $35.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018226 · doc4.xml · derivative · entry 1 Thomas Dolca · CIK 0001768239 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 1, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.